Cargando…
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
Discontinuation of treatment with monoclonal antibodies (mAb) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway leads to an increase in migraine frequency. We aimed to assess changes in free and total CGRP plasma concentrations after the discontinuation of CGRP(-receptor) mAbs. This prosp...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861447/ https://www.ncbi.nlm.nih.gov/pubmed/36678920 http://dx.doi.org/10.3390/pharmaceutics15010293 |
_version_ | 1784874843816067072 |
---|---|
author | Raffaelli, Bianca Terhart, Maria Fitzek, Mira Pauline Lange, Kristin Sophie Mecklenburg, Jasper Overeem, Lucas Hendrik Siebert, Anke Storch, Elisabeth Reuter, Uwe |
author_facet | Raffaelli, Bianca Terhart, Maria Fitzek, Mira Pauline Lange, Kristin Sophie Mecklenburg, Jasper Overeem, Lucas Hendrik Siebert, Anke Storch, Elisabeth Reuter, Uwe |
author_sort | Raffaelli, Bianca |
collection | PubMed |
description | Discontinuation of treatment with monoclonal antibodies (mAb) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway leads to an increase in migraine frequency. We aimed to assess changes in free and total CGRP plasma concentrations after the discontinuation of CGRP(-receptor) mAbs. This prospective analysis included 59 patients with migraine (n = 25 erenumab, n = 25 galcanezumab, n = 9 fremanezumab) who discontinued mAbs after ≥8 months of treatment. Patients were visited at the time of the last mAb injection (V1) and 16 weeks later (V2). For control, 30 migraine patients without preventive drug therapy were included. We measured free CGRP plasma concentrations in the erenumab and fremanezumab group and total CGRP concentrations in the galcanezumab group. Free CGRP plasma concentrations did not change after treatment discontinuation [erenumab: V1 31.2 pg/mL (IQR 25.8–45.6), V2 30.3 pg/mL (IQR 22.9–47.6), p = 0.65; fremanezumab V1 29.4 pg/mL (IQR 16.4–61.9), V2 34.4 (19.2–62.0), p = 0.86]. Controls had similar CGRP values of 32.6 pg/mL (IQR 21.3–44.6). Total CGRP concentrations in the galcanezumab group were 5439.3 pg/mL (2412.7–6338.1) at V1, and decreased to 1853.2 pg/mL (1136.5–3297.0) at V2 (p < 0.001). Cessation of treatment with CGRP(-R) mAbs did not have an impact on the free-circulating CGRP concentrations. Total CGRP decreased significantly after three months of treatment discontinuation. |
format | Online Article Text |
id | pubmed-9861447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98614472023-01-22 Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies Raffaelli, Bianca Terhart, Maria Fitzek, Mira Pauline Lange, Kristin Sophie Mecklenburg, Jasper Overeem, Lucas Hendrik Siebert, Anke Storch, Elisabeth Reuter, Uwe Pharmaceutics Article Discontinuation of treatment with monoclonal antibodies (mAb) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway leads to an increase in migraine frequency. We aimed to assess changes in free and total CGRP plasma concentrations after the discontinuation of CGRP(-receptor) mAbs. This prospective analysis included 59 patients with migraine (n = 25 erenumab, n = 25 galcanezumab, n = 9 fremanezumab) who discontinued mAbs after ≥8 months of treatment. Patients were visited at the time of the last mAb injection (V1) and 16 weeks later (V2). For control, 30 migraine patients without preventive drug therapy were included. We measured free CGRP plasma concentrations in the erenumab and fremanezumab group and total CGRP concentrations in the galcanezumab group. Free CGRP plasma concentrations did not change after treatment discontinuation [erenumab: V1 31.2 pg/mL (IQR 25.8–45.6), V2 30.3 pg/mL (IQR 22.9–47.6), p = 0.65; fremanezumab V1 29.4 pg/mL (IQR 16.4–61.9), V2 34.4 (19.2–62.0), p = 0.86]. Controls had similar CGRP values of 32.6 pg/mL (IQR 21.3–44.6). Total CGRP concentrations in the galcanezumab group were 5439.3 pg/mL (2412.7–6338.1) at V1, and decreased to 1853.2 pg/mL (1136.5–3297.0) at V2 (p < 0.001). Cessation of treatment with CGRP(-R) mAbs did not have an impact on the free-circulating CGRP concentrations. Total CGRP decreased significantly after three months of treatment discontinuation. MDPI 2023-01-15 /pmc/articles/PMC9861447/ /pubmed/36678920 http://dx.doi.org/10.3390/pharmaceutics15010293 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Raffaelli, Bianca Terhart, Maria Fitzek, Mira Pauline Lange, Kristin Sophie Mecklenburg, Jasper Overeem, Lucas Hendrik Siebert, Anke Storch, Elisabeth Reuter, Uwe Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies |
title | Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies |
title_full | Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies |
title_fullStr | Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies |
title_full_unstemmed | Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies |
title_short | Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies |
title_sort | change of cgrp plasma concentrations in migraine after discontinuation of cgrp-(receptor) monoclonal antibodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861447/ https://www.ncbi.nlm.nih.gov/pubmed/36678920 http://dx.doi.org/10.3390/pharmaceutics15010293 |
work_keys_str_mv | AT raffaellibianca changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT terhartmaria changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT fitzekmirapauline changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT langekristinsophie changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT mecklenburgjasper changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT overeemlucashendrik changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT siebertanke changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT storchelisabeth changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies AT reuteruwe changeofcgrpplasmaconcentrationsinmigraineafterdiscontinuationofcgrpreceptormonoclonalantibodies |